구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-4 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD) GenSight Biologics·Non-syndromic Retinitis Pigmentosa 1 trials |
|---|---|
Overview Program | Gene therapy: GS030-DP AND Medical device: GS030-MD |
Overview Company | GenSight Biologics |
Overview Modality | CGT |
Overview Target | Non-syndromic Retinitis Pigmentosa |
Overview Indication | Non-syndromic Retinitis Pigmentosa |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Low Dose Amitriptyline-Induced Electrical Storm Unmasking a Novel SCN5A and KCNQ1 Compound Genotype: Insights from Family Cascade Screening.. Cardiac toxicity from QT-prolonging drugs can precipitate malignant ventricular arrhythmias in susceptible individuals, and family screening may clarify inherited risk. We report a 33-year-old woman with a history of postpartum cardiac arrest treated with a … |
Clinical Safety signal | Low Dose Amitriptyline-Induced Electrical Storm Unmasking a Novel SCN5A and KCNQ1 Compound Genotype: Insights from Family Cascade Screening.. Cardiac toxicity from QT-prolonging drugs can precipitate malignant ventricular arrhythmias in susceptible individuals, and family screening may clarify inherited risk. We report a 33-year-old woman with a history of postpartum cardiac arrest treated with a … |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-4 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD) GenSight Biologics·Non-syndromic Retinitis Pigmentosa 1 trials |
|---|---|
Overview Program | Gene therapy: GS030-DP AND Medical device: GS030-MD |
Overview Company | GenSight Biologics |
Overview Modality | CGT |
Overview Target | Non-syndromic Retinitis Pigmentosa |
Overview Indication | Non-syndromic Retinitis Pigmentosa |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Low Dose Amitriptyline-Induced Electrical Storm Unmasking a Novel SCN5A and KCNQ1 Compound Genotype: Insights from Family Cascade Screening.. Cardiac toxicity from QT-prolonging drugs can precipitate malignant ventricular arrhythmias in susceptible individuals, and family screening may clarify inherited risk. We report a 33-year-old woman with a history of postpartum cardiac arrest treated with a … |
Clinical Safety signal | Low Dose Amitriptyline-Induced Electrical Storm Unmasking a Novel SCN5A and KCNQ1 Compound Genotype: Insights from Family Cascade Screening.. Cardiac toxicity from QT-prolonging drugs can precipitate malignant ventricular arrhythmias in susceptible individuals, and family screening may clarify inherited risk. We report a 33-year-old woman with a history of postpartum cardiac arrest treated with a … |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교